Want to see CLDX full AI Analyst Report?
Top Page
Celldex
(NASDAQ:CLDX)
Select Model
Select Model
Rating:57Neutral
Price Target:
$43.00
▲(21.88% Upside)
Action:Reiterated
Date:08/07/26
The score is primarily held back by weak financial performance (persistent and widening losses, near-zero TTM revenue, and accelerating cash burn) despite a strong, low-leverage balance sheet. Technicals are supportive with a strong uptrend, but overbought indicators add near-term risk. Valuation provides limited support due to negative earnings and no dividend, while the recent corporate event is modestly positive but includes a potential dilution consideration.
Positive Factors
Low leverage / strong balance sheet
Celldex’s balance sheet shows very low debt and sizable equity, materially reducing solvency and refinancing risk for a capital-intensive biotech. This durable financial flexibility supports multi-year clinical programs and provides runway to fund R&D without immediate operating revenue.
Negative Factors
Accelerating cash burn
Operating and free cash flows are persistently negative and have accelerated in the trailing twelve months, increasing funding pressure. This structural cash burn raises the probability of near-term financing needs and constrains the firm’s ability to self-fund pivotal trials without external capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
Celldex’s balance sheet shows very low debt and sizable equity, materially reducing solvency and refinancing risk for a capital-intensive biotech. This durable financial flexibility supports multi-year clinical programs and provides runway to fund R&D without immediate operating revenue.
Read all positive factors
Celldex (CLDX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.52B
Dividend YieldN/A
Average Volume (3M)1.19M
Price to Earnings (P/E)―
Beta (1Y)1.27
Revenue Growth-97.27%
EPS Growth-44.90%
CountryUS
Employees198
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.36
Shares Outstanding78,529,530
10 Day Avg. Volume933,099
30 Day Avg. Volume1,193,186
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)3.43
Price to Sales (P/S)1204.09
P/FCF Ratio-8.45
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue0.02
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$58.79Price Target Upside66.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-4.35
Revenue Forecast (FY)$2.21M
Celldex Business Overview & Revenue Model
Company Description
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both i...
How the Company Makes Money
Celldex is a clinical-stage biotechnology company and, as such, it typically does not generate recurring revenue from marketed products. Its earnings potential and reported revenue, when present, generally come from (a) collaboration and licensing...
Celldex Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
82
Very Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 112.00K | 1.50M | 7.02M | 6.88M | 2.36M | 4.65M |
| Gross Profit | -63.67M | 1.50M | -156.53M | -111.13M | -79.90M | -48.66M |
| EBITDA | -297.20M | -255.42M | -154.69M | -139.03M | -104.20M | -66.08M |
| Net Income | -300.59M | -258.80M | -157.86M | -141.43M | -112.33M | -70.51M |
Balance Sheet | ||||||
| Total Assets | 782.35M | 582.98M | 792.34M | 465.63M | 352.74M | 444.65M |
| Cash, Cash Equivalents and Short-Term Investments | 717.59M | 518.57M | 725.28M | 421.70M | 304.95M | 408.25M |
| Total Debt | 4.90M | 2.34M | 3.81M | 2.54M | 4.03M | 3.04M |
| Total Liabilities | 67.78M | 55.82M | 45.34M | 36.46M | 26.53M | 25.18M |
| Stockholders Equity | 714.56M | 527.16M | 747.00M | 429.17M | 326.20M | 419.48M |
Cash Flow | ||||||
| Free Cash Flow | -241.82M | -213.66M | -159.70M | -109.11M | -105.56M | -62.16M |
| Operating Cash Flow | -235.57M | -210.94M | -157.78M | -107.29M | -103.73M | -60.91M |
| Investing Cash Flow | -67.13M | 209.07M | -290.13M | -105.78M | 89.94M | -216.16M |
| Financing Cash Flow | 327.11M | 2.39M | 441.45M | 218.46M | 4.08M | 272.37M |
Celldex Technical Analysis
Positive
35.28
Price Trends
36.09
Positive
34.14
Positive
30.32
Positive
Market Momentum
2.10
Negative
65.27
Neutral
87.29
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLDX, the sentiment is Positive. The current price of 35.28 is below the 20-day moving average (MA) of 38.65, below the 50-day MA of 36.09, and above the 200-day MA of 30.32, indicating a bullish trend. The MACD of 2.10 indicates Negative momentum. The RSI at 65.27 is Neutral, neither overbought nor oversold. The STOCH value of 87.29 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLDX.
Celldex Risk Analysis
Celldex disclosed 2 risk factors in its most recent earnings report. Celldex reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Celldex Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $2.26B | -14.04 | -49.73% | ― | 1083.56% | 30.89% | |
60 Neutral | $3.05B | -9.63 | -40.51% | ― | 34.52% | 41.20% | |
59 Neutral | $2.57B | -11.49 | -37.99% | ― | -36.24% | 11.52% | |
59 Neutral | $2.76B | -7.88 | -76.09% | ― | -58.40% | -31.99% | |
57 Neutral | $3.52B | -9.77 | -52.36% | ― | -97.27% | -44.90% | |
52 Neutral | $3.18B | -10.40 | -50.56% | ― | -100.00% | 18.12% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
CLDX
Celldex
42.61
17.11
67.10%
NKTR
Nektar Therapeutics
75.92
48.66
178.50%
IOVA
Iovance Biotherapeutics
6.52
3.97
155.69%
NRIX
Nurix Therapeutics
27.19
16.61
156.99%
NUVB
Nuvation Bio
6.10
3.35
121.82%
IMNM
Immunome
26.42
16.14
157.00%
Celldex Corporate Events
Business Operations and StrategyShareholder Meetings
Celldex Shareholders Approve Expanded Equity Incentive Plan
Positive
Jun 26, 2026
At its June 25, 2026 annual meeting, Celldex Therapeutics stockholders approved an amendment to the company’s 2021 Omnibus Equity Incentive Plan, increasing the shares available for issuance by 3,400,000 to a total of 12,900,000 and clarifyi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.